NASDAQ · Biotechnology · USD

Bolt Biotherapeutics, Inc. (BOLT) Stock Analysis

Bolt Biotherapeutics, Inc. (BOLT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

BOLT

$4.14

−$0.17 (−3.94%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare BOLT with… →

BOLT Key Statistics

As of Oct 21, 2026

Trading

Open: $4.33
Previous Close: $4.31
Day's Range: 4.05–4.48
52-Week Range: 3.10–7.20
Volume: 34.47K
Beta: 1.01

Valuation

Market Cap: $7.78M
P/E Ratio: unprofitable
P/S ratio: 1.66
EPS (ttm): −16.51

Financials (FY)

Revenue (FY): $7.70M+0.07%
Net Income (FY): −$33.38M
Shares Outstanding: 1.93M
1-Year Return: −28.00%

Dividend and dates

Avg Volume: 27.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, BOLT closed at $4.14, −28.00% over 1 year.

Bolt Biotherapeutics, Inc. (BOLT) has a market capitalization of $7.78M.

In fiscal 2025, BOLT reported revenue of $7.70M.

BOLT Stock Return by Calendar Year

Bolt Biotherapeutics, Inc. (BOLT) return since Feb 2021: what $10,000 became

1 year: $10,000 $7,200; −28.00%
5 years: $10,000 $159; −98.41%
Since Feb 2021: $10,000 $64; −99.36%

If you had invested $10,000 in Bolt Biotherapeutics, Inc. (BOLT) at the close on February 5, 2021, the earliest close on record here, it would have been worth $64 at the close on October 21, 2026: −99.36% in total, −58.70% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−84.76%−73.47%−13.85%−52.23%−48.90%−24.29%

2021*20222023202420252026*

Year	Return
2026 (partial year)	−24.29%
2025	−48.90%
2024	−52.23%
2023	−13.85%
2022	−73.47%
2021 (partial year)	−84.76%

As of October 21, 2026.

BOLT Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$7.70M	−$33.38M	−433.7%
2024	$7.69M	−$63.12M	−820.8%
2023	$7.88M	−$69.20M	−878.6%
2022	$5.73M	−$88.10M	−1,537.8%

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$7.70M	—	−$34.63M	−$33.38M	−433.7%
2024	$7.69M	—	−$68.24M	−$63.12M	−820.8%
2023	$7.88M	—	−$76.20M	−$69.20M	−878.6%
2022	$5.73M	—	−$90.32M	−$88.10M	−1,537.8%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

BOLT Valuation vs Biotechnology Median

Median of 608 stocks

Metric	BOLT	Biotechnology median	vs median
P/S ratio	1.66	13.30	0.1x the median

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Analysis

Data-derived

Company Overview

Bolt Biotherapeutics, Inc. (BOLT) is capitalised at $7.78M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 23 employees.

The 52-week range on file runs from $3.10 to $7.20. BOLT last closed at $4.14 on October 21, 2026. That is −$0.17 (−3.94%) against the previous close. The latest close sits 33.55% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $7.70M. Against the prior fiscal year total of $7.69M, that is a change of +0.07%. The same year closed with a net loss of $33.38M. Earnings per share on a trailing basis come to −16.51.

Across the 4 fiscal years on file, revenue moves from $5.73M in 2022 to $7.70M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. Measured against sales, the shares trade at 1.66 times revenue. On price-to-sales that is 0.1 times the Biotechnology median of 13.3. 608 Biotechnology companies report these metrics, and the medians quoted come from that group.

Beta against the wider market is reported at 1.01. Annualized volatility over the trailing 5 years is 74.51%. The trailing one-year total return is −28.00%. Across 5 years the annualized return works out at −56.31%.

Growth & Income

The record shows no dividend for BOLT.

Across the complete calendar years on file, 2023 returned −13.85% and 2022 returned −73.47%. Of the 4 complete calendar years on file, 0 finished higher. 2026 is still running; the total return is −24.29% year to date.

Peer Comparison

Bolt Biotherapeutics, Inc. (BOLT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Bolt Biotherapeutics, Inc.	BOLT	$7.78M	—
Vertex Pharmaceuticals Incorporated	VRTX	$132.95B	30.4
Moderna, Inc.	MRNA	$98.14B	—
Regeneron Pharmaceuticals, Inc.	REGN	$82.95B	19.9

The Biotechnology industry average P/E ratio is 16.6x. Bolt Biotherapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

MRNA

Moderna, Inc.

$98.14B

REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

ARGX

argenx SE

$55.97B

ONC

BeOne Medicines AG

$43.97B

RVMD

Revolution Medicines, Inc.

$41.64B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

JNJ

Johnson & Johnson

$621.22B

ABBV

AbbVie Inc.

$503.27B

UNH

UnitedHealth Group Incorporated

$374.30B

MRK

Merck & Co., Inc.

$369.78B

View all Healthcare stocks →

About Bolt Biotherapeutics, Inc.

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies for the treatment of cancer. The company's pipeline products include BDC-4182, a next-generation Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; CEA ISAC, a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 for the treatment of solid tumors, including colorectal, non-small cell lung, pancreatic, and breast; and PD-L1 ISAC, a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker to target both tumor and immune cells for the treatment of tumor regression and immunological memory. The company has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, Inc.; and a license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.

Visit website →